Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy

References

• Harris ED Jr. Rheumatoid arthritis: pathophysiology and impli-cations for therapy. N Engl J Med. 1990;322:1277–89.
   PubMed Web of Science ®Google Scholar
• Cush JJ, Lipsky PE. Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheu-matoid arthritis. Arthritis Rheum. 1988;31:1230–8.
   PubMed Web of Science ®Google Scholar
• Paleolog EM. Angiogenesis: a critical process in the pathogenesis of RA-a role for VEGF? Br J Rheumatol. 1996;35:917-9.
   Google Scholar
• Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Ki-shimoto T, et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. 1993;53: 851–6.
   Google Scholar
• Choy EHS, Isenberg DA, Ganood T, Farrow S, Ioannou Y, Bird H, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis. Arthritis Rheum. 2002;46:3143–50.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Yoshizaki K, Maeda K, Kuritani T, Deguchi H, Sato B, et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol. 2003;30:1426–35.
   Google Scholar
• Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50:1761–9.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X-ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162–7.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum. 1992;35:498–502.
   PubMed Web of Science ®Google Scholar
• Fransen J, Creemers MC, Van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DA528) with the ARA preliminary remission criteria. Rheumatology. 2004;43: 1252–5.
   Google Scholar
• Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum. 2000;43:1478–87.
   Google Scholar
• Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54:2817–29.
   PubMed Web of Science ®Google Scholar
• Kashiwazaki S, Ichikawa Y, Sugawara S, Nagaya I, Kawai S, Hakota M, et al. Determination of the clinical optimal dose of L-377 (methotrexate capsule) for the treatment of rheumatoid arthritis (in Japanese). Ensyo. 1996;16:437–58.
   Google Scholar
• Ito S, Gross WL, Reinhold-Keller E, Gause A, Aries P, Ruther W, et al. Rheumatology in Japan, Germany, and Egypt: a comparison of medical practices. Acta Medica et Biologica. 2006;54:51–8.
   Google Scholar
• Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K, et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheu-matoid arthritis. Arthritis Rheum. 2003;48:1521–9.
   PubMed Web of Science ®Google Scholar
• Nagashima M, Yoshino S, Ishiwata T, Asano G. Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. J Rheumatol. 1995;22:1624–30.
   PubMed Web of Science ®Google Scholar
• Kasama T, Kobayashi K, Yajima N, Shiozawa F, Yoda Y, Takeuchi HT, et al. Expression of vascular endothelial growth factor by synovial fluid neutrophils in rheumatoid arthritis (RA). Clin Exp Immunol. 2000;121:533–8.
   PubMedGoogle Scholar
• Bottomley MJ, Webb NJA, Watson CJ, Holt PJL, Freemont AJ, Brenchley PEC. Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor (VEGF): specific up-regulation by tumor necrosis factor-alpha (TNF-a) in synovial fluid. Clin Exp Immunol. 1999;117:171–6.
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nat Med. 1995;1:27–31.
   PubMed Web of Science ®Google Scholar
• Colville-Nash PR, Scott DL. Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications. Ann Rheum Dis. 1992;51:919–25.
   PubMed Web of Science ®Google Scholar
• Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989;246:1309–12.
   PubMed Web of Science ®Google Scholar
• Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, et al. Tumor vascular permeability factor stimu-lates endothelial cell growth and angiogenesis. J Clin Invest. 1989;84 :1470–8.
   PubMed Web of Science ®Google Scholar
• Koch AE, Harlow LA, Haines GK, Amento EP, Unemori EN, Wong WL, et al. Vascular endothelial growth factor: a cytokine modulating endothelial function in rheumatoid arthritis. J Immunol. 1994;152:4149–56.
   PubMed Web of Science ®Google Scholar
• Ballara S, Taylor PC, Reusch P, Marme D, Feldmann M, Maini RN, et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum. 2001;44:2055–64.
   PubMed Web of Science ®Google Scholar
• Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with inflix-imab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098–104.
   Google Scholar